about
HLA class I variation in the West African Pygmies and their genetic relationship with other African populationsTranscriptional regulation of ULBP1, a human ligand of the NKG2D receptor.NKG2D ligands: key targets of the immune response.Clinical differences between men and women with psoriatic arthritis: relevance of the analysis of genes and polymorphisms in the major histocompatibility complex region and of the age at onset of psoriasis.MHC class I region plays a role in the development of diverse clinical forms of celiac disease in a Saharawi population.Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands.MHC class I chain-related gene B promoter polymorphisms and celiac disease.Cloning and characterization of human complement component C7 promoter.Extended human leukocyte antigen haplotype EH18.1 influences progression to hepatocellular carcinoma in patients with hepatitis C virus infection.The HLA-B*5703 allele confers susceptibility to the development of spondylarthropathies in Zambian human immunodeficiency virus-infected patients with slow progression to acquired immunodeficiency syndrome.HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population.Association of MHC class I related gene B (MICB) to celiac disease.Genetic influence of the nonclassical major histocompatibility complex class I molecule MICB in multiple sclerosis susceptibilitySoluble MHC class I chain-related protein B serum levels correlate with disease activity in relapsing–remitting multiple sclerosisTranscriptional regulation of MICA and MICB: A novel polymorphism in MICB promoter alters transcriptional regulation by Sp1MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibilityClinical behavior of multiple sclerosis is modulated by the MHC class I-chain-related gene ANK Cell-Based Immunotherapy in Cancer MetastasisThe OTF3 gene polymorphism confers susceptibility to psoriasis independent of the association of HLA-Cw*0602Psoriasis vulgaris and psoriatic arthritis share a 100 kb susceptibility region telomeric to HLA-CPolymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish populationHigh variability of HLA-B27 alleles in ankylosing spondylitis and related spondyloarthropathies in the population of northern SpainGenetic variability, molecular evolution, and geographic diversity of HLA-B27New insights regarding HLA-B27 diversity in the Asian populationMICA-A5.1 allele is associated with atypical forms of celiac disease in HLA-DQ2-negative patientsThe role of HLA-B27 polymorphism and molecular mimicry in spondylarthropathyHigh serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's diseaseThe region of 150 kb telometic to HLA-C is associated with psoriasis in the Jewish populationExpression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA sheddingHLA-DR17 is associated with enthesitis in psoriatic arthritisComment on "Proteasome regulation of ULBP1 transcription"Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemiaSelective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceNK Cells in the Treatment of Hematological MalignanciesMechanisms of Resistance to NK Cell ImmunotherapyMechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
P50
Q28205079-6128A2CF-3646-4BCF-8AB5-90DF95F36B08Q34556241-D315CF6F-3E73-43DF-B243-CE8BAC78ED36Q34792486-11CDA00E-C7E4-4185-BD7B-C4DE5BA54DE8Q36838100-9FF7A59E-91EE-4E9E-8BCE-93DF4DF551E9Q39197136-6E2AFE17-D3DB-4EB9-9346-0B19EE831F5AQ40134133-5C7AFB63-263D-4BC1-B7DF-1300E610FA22Q40280276-7205D2D0-76A8-45DB-B30A-6DC57FEEFF0DQ40669247-71565CD4-2404-473E-A24F-009E9BCA026BQ44785802-09854288-795A-4391-8281-A735792E71D9Q45527277-6778E1FD-7FD3-4629-AE82-EBBFB60E6A84Q46017171-355B3088-9B13-44BF-B893-2909DE1E23D6Q46199343-9F4BB4CA-3AB0-4BD7-9B58-E4FA6CF81F2AQ47751097-1583A507-1396-4E1E-9A92-2496ED3A4079Q61441005-F1A80664-45F1-481E-A093-346116AE8F5AQ61441006-A944BCD1-3E12-45E4-B074-8B9D53A22EF9Q61441007-40FF0780-8F38-436A-A64A-9F246737231CQ61441008-157ABE3C-3872-451E-9144-BFF7EAA360FAQ61441009-9059104E-396F-4367-998F-DA1C364B3499Q61811846-65BCC581-EF83-4B4E-AA69-2F9EC828D4F2Q73167558-8A52DED1-F5A5-4DD1-8B39-30D54F5F3AD1Q73350619-08CA341B-5D1F-4EBE-80DE-DFE5A0258125Q73965652-CC5781DC-10EC-4F6E-9239-2DEC5EBA4B5FQ74471843-22D054A3-396F-4117-91F8-E280D60242FFQ74480797-616D2F26-0E2A-4F58-A764-D206BF03F7FEQ77464629-CCF13EF8-78F0-428C-BD54-9C1F3CFD1345Q77681308-0159D5B9-3D96-4C61-925F-2258596399DEQ77729652-592BC7B0-BED1-44AD-9D4E-2CE525E63C3FQ78309897-7F9E793C-FB06-450A-B622-97915736F32EQ81503136-FBA19F35-CCFD-49C3-BFC0-E60C7A6B1B50Q83170841-2A210AB2-651E-489F-8D44-48C98E302CCBQ84059555-BCBB9A2D-FE9C-49FD-8DA2-F100CCA57745Q84574609-A0C9291C-A014-44ED-B05E-2AA938E7263CQ85039045-0B04DCBF-AC00-4043-AB71-B46F3C8FF160Q89554723-667CB161-16F0-4FF1-A45E-BFB52889850EQ90384454-5FD0BEA8-2881-4A27-ABE4-58C9A8D6A8DDQ91779268-AD5BE57B-9205-4213-9689-D634F1D9C472Q95929958-DDA03506-E848-4080-84FE-F149E16AF301
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Segundo González
@ast
Segundo González
@en
Segundo González
@es
Segundo González
@nl
Segundo González
@sl
type
label
Segundo González
@ast
Segundo González
@en
Segundo González
@es
Segundo González
@nl
Segundo González
@sl
prefLabel
Segundo González
@ast
Segundo González
@en
Segundo González
@es
Segundo González
@nl
Segundo González
@sl
P106
P1153
7202199907
P21
P31
P496
0000-0003-4631-9255